Establishing Clinical Pharmacology Guidelines to Address Regulatory Approval Uncertainties

The U.S. Food and Drug Administration (FDA) has finalized its guidance on Food Effect (FE) for oral new drugs and investigational new drugs (IND/NDA), initially issued in 2022 and revised in May 2026. This guidance serves as a crucial clinical pharmacology benchmark that global biotech and pharmaceutical companies must adhere to from the early stages of R&D. The revised guidance aims to significantly reduce uncertainties in the regulatory approval process by controlling the variability in bioavailability (BA) caused by food on the absorption and metabolism of oral drugs in patients. By proactively addressing the risk of receiving Complete Response Letters (CRL) due to poorly defined dietary requirements in the clinical trial design, the guidance maximizes the overall research and development (R&D) efficiency of the pharmaceutical industry.

Controlling and Evaluating Bioavailability Variability Through Standardized Clinical Trial Design

Companies leading clinical trials must, in accordance with this guidance, design early-stage Food Effect (FE) studies using a randomized, crossover design with healthy subjects. Comparing pharmacokinetic (PK) data in the fasted and high-fat meal conditions provides essential baseline data for precisely tracking significant changes in the drug's maximum plasma concentration (Cmax) and area under the curve (AUC). In particular, clearly defining the exposure-response relationship from the early clinical stages plays a critical role in preventing dose-setting errors in Phase 3 clinical trials and demonstrating patient safety.

Optimizing Labeling Strategies to Secure Market Competitiveness and Medication Adherence

From the perspective of market competitiveness and medication adherence, the standardized clinical trial design outlined in this guidance can be a powerful factor determining commercial success. For oral drugs that require multiple daily doses, strict fasting requirements can significantly reduce actual patient adherence, potentially leading to a loss of competitiveness compared to the standard of care (SoC) after market launch. Therefore, pharmaceutical companies aim to obtain optimal drug labeling, such as 'take with or without food,' based on clinical data, which will become a key marketing differentiator for future blockbuster drugs.

Highlighting Clinical Protocol Due Diligence as a Key Indicator in Capital Market Investment Reviews

From the perspective of venture capital (VC) and capital market investors, a company's ability to design food effect studies in the clinical trial design phase is a key indicator of its technological capabilities. Companies that fail to systematically prepare for drug-food interaction studies in the early pipeline stages face a higher risk of delayed regulatory review or requests for additional clinical trials, which could indefinitely extend the time to exit. When selecting investment opportunities, it is essential to conduct thorough due diligence to assess whether the clinical protocols in the pipeline thoroughly reflect the clinical pharmacology guidelines outlined in this guidance, thereby filtering out development and regulatory risks in advance.